Key regions: United Kingdom, Brazil, Europe, France, Canada
Anti-fibrinolytic drugs are used to prevent blood clots from breaking down and are commonly used in surgical procedures. In Ivory Coast, the market for these drugs has been experiencing steady growth in recent years.
Customer preferences: Medical professionals in Ivory Coast prefer anti-fibrinolytic drugs due to their effectiveness in preventing excessive bleeding during and after surgical procedures. This preference is driven by the need to reduce the risk of complications and improve patient outcomes.
Trends in the market: The market for anti-fibrinolytic drugs in Ivory Coast has seen steady growth in recent years. This growth can be attributed to several factors, including an increase in the number of surgical procedures being performed, an aging population, and an increase in chronic diseases such as cardiovascular disease and diabetes. Additionally, the government's efforts to improve healthcare infrastructure and access to medical services have contributed to the growth of the market.
Local special circumstances: Ivory Coast has a relatively underdeveloped healthcare system, with limited access to medical facilities in certain regions. However, the government has taken steps to improve healthcare infrastructure, including the construction of new hospitals and clinics. This has helped to increase access to medical services and has contributed to the growth of the anti-fibrinolytic drugs market.
Underlying macroeconomic factors: Ivory Coast has experienced steady economic growth in recent years, driven by a strong agricultural sector and an increase in foreign investment. This growth has led to an increase in disposable income and an expansion of the middle class, which has contributed to increased demand for healthcare services. Additionally, the government's efforts to promote economic growth and development have helped to create a favorable business environment for pharmaceutical companies operating in the country.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
